DCGI tells manufacturers, exporters not to submit same batch no. of cough syrup to two different laboratories

Published On 2023-08-10 10:59 GMT   |   Update On 2023-08-10 10:59 GMT
Advertisement

Safeguarding public health, through a recent notification, the Drug Controller General of India (DCGI) has notified all drug manufacturers' associations and exporters not to submit the same batch of cough syrup to more than one laboratory at a time, as this practice is highly objectionable and not acceptable from a regulatory standpoint.

This came when two different government laboratories accredited by the National Accreditation Board for Testing and Calibration (NABL) received cough syrup from the same manufacturer/exporter with the same batch number for testing purposes.

For more details, check out the link given below:

Do Not Submit Same Batch No. Of Cough Syrup To Two Different Laboratories: DCGI Tells Manufacturers, Exporters


Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News